Selected research
Industry Research
Oral Hypoglycemic Agents (OHAs) Industry Research Report 2026
Market perspective
The global Oral Hypoglycemic Agents (OHAs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Oral Hypoglycemic Agents (OHAs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Oral Hypoglycemic Agents (OHAs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Oral Hypoglycemic Agents (OHAs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Oral Hypoglycemic Agents (OHAs) include Bristol-Myers Squibb, Double-Crane Pharmaceutical, Novonordisk, Sanofi-Aventis, Servier, Bayer, Wanbang Biopharmaceuticals, GlaxoSmithKline and Guangzhou Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Oral Hypoglycemic Agents (OHAs) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oral Hypoglycemic Agents (OHAs) Market by Company
Bristol-Myers Squibb
Double-Crane Pharmaceutical
Novonordisk
Sanofi-Aventis
Servier
Bayer
Wanbang Biopharmaceuticals
GlaxoSmithKline
Guangzhou Pharmaceutical
Huadong Medicine
Pfizer
Oral Hypoglycemic Agents (OHAs) Segment by Type
Alpha-Glucosidase Inhibitors
Metformin
Sulfonylureas
Thiazolidinediones
Oral Hypoglycemic Agents (OHAs) Segment by Application
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Oral Hypoglycemic Agents (OHAs) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents (OHAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents (OHAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents (OHAs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Oral Hypoglycemic Agents (OHAs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Oral Hypoglycemic Agents (OHAs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Oral Hypoglycemic Agents (OHAs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Alpha-Glucosidase Inhibitors
- Metformin
- Sulfonylureas
- Thiazolidinediones
Applications
- Type 2 Diabetes Mellitus
- Type 1 Diabetes Mellitus
Companies covered
- Bristol-Myers Squibb
- Double-Crane Pharmaceutical
- Novonordisk
- Sanofi-Aventis
- Servier
- Bayer
- Wanbang Biopharmaceuticals
- GlaxoSmithKline
- Guangzhou Pharmaceutical
- Huadong Medicine
- Pfizer
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Oral Hypoglycemic Agents (OHAs) Market Size (2021-2032)
- 2.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales (2021-2032)
- 2.2.3 Global Oral Hypoglycemic Agents (OHAs) Market Average Price (2021-2032)
- 2.3 Oral Hypoglycemic Agents (OHAs) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Alpha-Glucosidase Inhibitors
- 2.3.3 Metformin
- 2.3.4 Sulfonylureas
- 2.3.5 Thiazolidinediones
- 2.4 Oral Hypoglycemic Agents (OHAs) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Type 2 Diabetes Mellitus
- 2.4.3 Type 1 Diabetes Mellitus
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Oral Hypoglycemic Agents (OHAs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Oral Hypoglycemic Agents (OHAs) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Oral Hypoglycemic Agents (OHAs) Revenue of Manufacturers (2021-2026)
- 3.4 Global Oral Hypoglycemic Agents (OHAs) Average Price by Manufacturers (2021-2026)
- 3.5 Global Oral Hypoglycemic Agents (OHAs) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Oral Hypoglycemic Agents (OHAs), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Oral Hypoglycemic Agents (OHAs), Product Type & Application
- 3.8 Global Manufacturers of Oral Hypoglycemic Agents (OHAs), Established Date
- 3.9 Global Oral Hypoglycemic Agents (OHAs) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol-Myers Squibb
- 4.1.1 Bristol-Myers Squibb Company Information
- 4.1.2 Bristol-Myers Squibb Business Overview
- 4.1.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.1.5 Bristol-Myers Squibb Recent Developments
- 4.2 Double-Crane Pharmaceutical
- 4.2.1 Double-Crane Pharmaceutical Company Information
- 4.2.2 Double-Crane Pharmaceutical Business Overview
- 4.2.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.2.5 Double-Crane Pharmaceutical Recent Developments
- 4.3 Novonordisk
- 4.3.1 Novonordisk Company Information
- 4.3.2 Novonordisk Business Overview
- 4.3.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novonordisk Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.3.5 Novonordisk Recent Developments
- 4.4 Sanofi-Aventis
- 4.4.1 Sanofi-Aventis Company Information
- 4.4.2 Sanofi-Aventis Business Overview
- 4.4.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.4.5 Sanofi-Aventis Recent Developments
- 4.5 Servier
- 4.5.1 Servier Company Information
- 4.5.2 Servier Business Overview
- 4.5.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Servier Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.5.5 Servier Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 Wanbang Biopharmaceuticals
- 4.7.1 Wanbang Biopharmaceuticals Company Information
- 4.7.2 Wanbang Biopharmaceuticals Business Overview
- 4.7.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.7.5 Wanbang Biopharmaceuticals Recent Developments
- 4.8 GlaxoSmithKline
- 4.8.1 GlaxoSmithKline Company Information
- 4.8.2 GlaxoSmithKline Business Overview
- 4.8.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.8.5 GlaxoSmithKline Recent Developments
- 4.9 Guangzhou Pharmaceutical
- 4.9.1 Guangzhou Pharmaceutical Company Information
- 4.9.2 Guangzhou Pharmaceutical Business Overview
- 4.9.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.9.5 Guangzhou Pharmaceutical Recent Developments
- 4.10 Huadong Medicine
- 4.10.1 Huadong Medicine Company Information
- 4.10.2 Huadong Medicine Business Overview
- 4.10.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.10.5 Huadong Medicine Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Oral Hypoglycemic Agents (OHAs) Product Portfolio
- 4.11.5 Pfizer Recent Developments
5 Global Oral Hypoglycemic Agents (OHAs) Market Scenario by Region
- 5.1 Global Oral Hypoglycemic Agents (OHAs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2021-2032
- 5.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2021-2026
- 5.2.2 Global Oral Hypoglycemic Agents (OHAs) Sales by Region: 2027-2032
- 5.3 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2021-2032
- 5.3.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2021-2026
- 5.3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Region: 2027-2032
- 5.4 North America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
- 5.4.1 North America Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
- 5.4.3 North America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
- 5.5.1 Europe Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
- 5.5.3 Europe Oral Hypoglycemic Agents (OHAs) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Oral Hypoglycemic Agents (OHAs) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
- 5.7.1 South America Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
- 5.7.3 South America Oral Hypoglycemic Agents (OHAs) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Oral Hypoglycemic Agents (OHAs) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032)
- 6.1.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Type (2021-2032)
- 6.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2021-2032)
- 6.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Type (2021-2032)
- 6.3 Global Oral Hypoglycemic Agents (OHAs) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032)
- 7.1.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Application (2021-2032)
- 7.2 Global Oral Hypoglycemic Agents (OHAs) Revenue by Application (2021-2032)
- 7.2.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Application (2021-2032)
- 7.3 Global Oral Hypoglycemic Agents (OHAs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Oral Hypoglycemic Agents (OHAs) Value Chain Analysis
- 8.1.1 Oral Hypoglycemic Agents (OHAs) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Oral Hypoglycemic Agents (OHAs) Production Mode & Process
- 8.2 Oral Hypoglycemic Agents (OHAs) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Oral Hypoglycemic Agents (OHAs) Distributors
- 8.2.3 Oral Hypoglycemic Agents (OHAs) Customers
9 Global Oral Hypoglycemic Agents (OHAs) Analyzing Market Dynamics
- 9.1 Oral Hypoglycemic Agents (OHAs) Industry Trends
- 9.2 Oral Hypoglycemic Agents (OHAs) Industry Drivers
- 9.3 Oral Hypoglycemic Agents (OHAs) Industry Opportunities and Challenges
- 9.4 Oral Hypoglycemic Agents (OHAs) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst